Diabetic Foot Ulcer Treatment Market Expected to Witness a High Jump as the Market is Projected to Grow with a CAGR of 17.0% During the Study Period (2018-2030) | DelveInsight

LAS VEGAS, March 1, 2021 /PRNewswire/ -- DelveInsight's "Diabetic Foot Ulcer (DFU) Market" report provides a thorough comprehension of the Diabetic Foot Ulcer, historical and forecasted epidemiology, and the Diabetic Foot Ulcer market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Diabetic Foot Ulcer market report also proffers an analysis of recent Diabetic Foot Ulcer treatment algorithm/practice, market drivers, market barriers, and unmet medical needs. 

Some of the vital points of the Diabetic Foot Ulcer Market Research Report

• Diabetic Foot Ulcer (DFU) is one of the most significant and devastating complications of diabetes mellitus, and probably the major component of the diabetic foot. According to American Podiatric Medical Association (APMA), diabetes is the leading cause of non-traumatic lower extremity amputations in the United States, and approximately 14-24% of patients with diabetes who develop a foot ulcer will require an amputation. Foot ulceration precedes 85% of diabetes-related amputations.
• The gold standard for Diabetic Foot Ulcer treatment includes debridement of the wound, management of any infection, revascularization procedures when indicated, and off-loading of the ulcer. Currently, the market is mainly dominated by off-label generic drugs such as analgesics and anti-infectives, around 78% of the current market is captured by these two classes of drugs. 
• There is only one drug, Regranex (Becaplermin), which the FDA has approved. Regranex gel uses a Platelet-derived growth factor (PDGF) for the Diabetic Neuropathic Ulcer treatment formulated to act as a first-line treatment following effective ulcer care. The US FDA had approved the biologics license application of Becaplermin (OMJ Pharmaceuticals, Inc) in December 1997.
• Market players such as Amniox (TissueTech), Helixmith Co., Ltd., Oneness Biotech Co., Ltd., Ticeba GmbH, RHEACELL GmbH & Co. KG, and Lakewood-Amedex Inc, Aurealis Therapeutics, Biotherapy Services, Microbion Corporation, Mallinckrodt, and many others are involved in developing Diabetic Foot Ulcer drugs. 
• The emerging therapies under development expected to provide efficient therapeutic approaches with a novel mechanism of action to treat Diabetic Foot Ulcer patients. Among the emerging therapies, cryopreserved umbilical cord TTAX01 allograft from Amniox Medical (a TissueTech) is expected to garner the highest patient share owing to promising efficacy signals shown in phase II trial and the company is well on track with two-phase III multicenter randomized controlled clinical trials.

For additional information on Market Impact by Therapies, visit: Diabetic Foot Ulcer Treatment Market Analysis

A Diabetic Foot Ulcer is a complex chronic wound commonly in type 1 and type 2 diabetes mellitus patients. Diabetes patients can quickly develop foot ulcers and foot pain as they are a common complication of poorly controlled diabetes, but good foot care can help prevent them. As per DelveInsight's analysis, the total Diabetic Foot Ulcer prevalent cases were 5,994,978 cases in the 7MM (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan) in 2020 and are expected to grow during the study period of 2018–2030. 

For more information on Diabetic Foot Ulcer Market, click here @ Diabetic Foot Ulcer Market Infographic 

The DFU Market Report provides historical as well as forecasted epidemiological analysis segmented into:

• Total Prevalent Cases of Diabetic Foot Ulcer
• Total Diagnosed Cases of Diabetic Foot Ulcer
• Gender-specific cases of Diabetic Foot Ulcer
• Age-specific Cases of Diabetic Foot Ulcer
• Diabetic Foot Ulcer cases by severity/chronicity of wound
• Treated cases of Diabetic Foot Ulcer

Request sample report for more insights @ Diabetic Foot Ulcer Market Size

Diabetic Foot Ulcer Therapeutics Market 

The therapy goals for Diabetic Foot Ulcer patients are wound closure, eradication of clinical evidence of infection, and the avoidance of soft tissue loss and amputations. 

Currently, Diabetic Foot Ulcer treatment strategies mainly include non-surgical treatment for mild and moderate ulcers and surgical treatment for ulcers classified as severe. Non-surgical treatment options mainly include simple daily wound care, using growth factors and skin substitutes for wound repair, antibiotics for the deep infection, drainage, and cellulitis. Whereas surgical treatment options mainly include debridement, removal of unhealthy tissue, and vascular surgeries to induce better blood flow. The development of growth factor for treatment represents a significant therapeutic advance for diabetic neuropathic foot ulcers with adequate blood supply. 

Platelet-derived growth factor (PDGF) is one of the primary growth factors involved in healing. Regranex (Becaplermin) is the only drug, which uses PDGF and is approved by the US FDA. Regranex (Becaplermin) is a topical gel labeled for adjunctive treatment of stage III and IV diabetic neuropathic ulcers of the lower extremities. Becaplermin is a recombinant human platelet-derived growth factor; therefore, it promotes wound healing by enhancing granulation tissue formation. This recombinant growth factor is delivered in a topical aqueous-based sodium carboxymethylcellulose (NaCMC) gel. Regranex gel is used to treat diabetic neuropathic ulcers, formulated to act as a first-line treatment following effective ulcer care. 

Diabetic Foot Ulcer Emerging Therapies Along with Key Players 

The companies are working to assess challenges and seek opportunities that could influence Diabetic Foot Ulcer R&D. The therapies under development are focused on novel approaches to treat Diabetic Foot Ulcer. Major players are involved in developing Diabetic Foot Ulcer therapies. 

• TTAX01 (Neox Cord 1K): Amniox (TissueTech)
• Engensis (VM202; Donaperminogene Seltoplasmid): Helixmith 
• ON101 (WH-1): Oneness Biotech
• Allo-APZ2-DFU (ABCB5 positive MSCs): Rheacell (a subsidiary of Ticeba)
• Bisphosphocin Nu-3: Lakewood-Amedex
• AUP1602-C: Aurealis Therapeutics
• RAPID Biodynamic PRP Haematogel: Biotherapy Services
• MBN-101 (Pravibismane): Microbion Corporation 
• ExpressGraft (C9T1 Skin Tissue): Mallinckrodt

And many others.

Concluding thoughts on Diabetic Foot Ulcer Market Growth Dynamics 

The dynamics of the Diabetic Foot Ulcer market are anticipated to change in the coming years because of the DFU Market Drivers such as an increase in diabetes cases, a rich emerging pipeline, the development of new treatment modalities, and increased awareness across health care systems. However, the burden of high cost in Diabetic Foot Ulcer treatment, post-operative challenges in Diabetic Foot Ulcer patients, and unavailability of specialists lead to restraints in Diabetic Foot Ulcer market growth. 

Scope of the Diabetic Foot Ulcer Market Insight Report 

• Geography Covered: 7MM - The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan.
• Study Period: 3-year historical and 10-year forecasted analysis (2018-2030).
• Diabetic Foot Ulcer Markets Segmentation: By Geographies and By Diabetic Foot Ulcer Therapies (Historical and Forecasted, Current and Upcoming) 
• Leading Market Companies investigating its candidates for Diabetic Foot Ulcer: Amniox (TissueTech), Helixmith Co., Ltd., Oneness Biotech Co., Ltd., Ticeba GmbH, RHEACELL GmbH & Co. KG, and Lakewood-Amedex Inc, Aurealis Therapeutics, Biotherapy Services, Microbion Corporation, Mallinckrodt, and several others.
• Analysis: Comparative and conjoint analysis of emerging therapies.
• Case Studies
• KOL's Views
• Analyst's View

Request for a Webex demo of the report @ Global Diabetic Foot Ulcer Treatment Market Size

Table of Contents 

Browse detailed TOC with charts, figures, tables @ DFU Market Size Report 

View Related Reports       

• Diabetic Foot Ulcers Epidemiology Forecast Analysis 

DelveInsight's Diabetic foot ulcers (DFUs) - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Diabetic foot ulcers (DFUs) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

• Diabetic Foot Ulcers Pipeline Analysis 

Diabetic Foot Ulcers Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Diabetic Foot Ulcers market.

• Dementia with Diabetes Market Analysis 

DelveInsight's Dementia with Diabetes - Market Insights, Epidemiology and Market Forecast - 2030 report provides an in-depth understanding of historical and forecasted epidemiology.

• Diabetes Market Analysis 

DelveInsight's Diabetes Market Insights, Epidemiology and Market Forecast - 2030 report provides thorough insights on epidemiology and market trends.

• Diabetic Foot Market Analysis 

DelveInsight's Diabetic Foot - Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

• Diabetic Gastroparesis Market Analysis 

Diabetic Gastroparesis Market Research Report presents a detailed analysis of the market listing Diabetic Gastroparesis Epidemiology, Drug therapies.

• Diabetic Ketoacidosis Market Analysis 

DelveInsight's Diabetic Ketoacidosis (DKA) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

• Diabetic Kidney Disease Market Analysis 

DelveInsight's Diabetic Kidney Disease (DKD) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

• Diabetic Macular Edema Market Analysis 

DelveInsight's Diabetic Macular Edema (DME) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

• Diabetic Nephropathy Market Analysis 

DelveInsight's Diabetic Nephropathy - Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed overview of the disease.

• Diabetic Neuropathy Market Analysis 

DelveInsight's "Diabetic Neuropathy - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of Diabetic Neuropathy, historical and forecasted epidemiology.

• Diabetic Peripheral Neuropathy Market Analysis 

DelveInsight's Diabetic Peripheral Neuropathy - Market Insights, Epidemiology and Market Forecast - 2030 report provides an in-depth understanding of historical and forecasted epidemiology.

• Diabetic Retinopathy Market Analysis 

DelveInsight's Diabetic Retinopathy Market Insights, Epidemiology and Market Forecast 2030 report provides an overview of the disease & understanding of historical & forecasted epidemiology.

• Diabetes Pen Market Analysis 

Diabetes Pen Market Insights, Competitive Landscape and Market Forecast-2025 report delivers an in-depth understanding of the Diabetes Pen Market and the historical and forecasted epidemiology.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. 

Contact Us:

Shruti Thakur
[email protected]
+1(919)321-6187 
www.delveinsight.com

View original content:http://www.prnewswire.com/news-releases/diabetic-foot-ulcer-treatment-market-expected-to-witness-a-high-jump-as-the-market-is-projected-to-grow-with-a-cagr-of-17-0-during-the-study-period-20182030--delveinsight-301237080.html

SOURCE DelveInsight Business Research, LLP